Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Odintsov

Showing results (181-190 of 196) with videos related to

Pageof 20
Sort By:
Virchows Archiv : an International Journal of Pathology|May 21, 2026
Clinicopathologic characterization of renal tumors with Folliculin (FLCN) biallelic inactivationStephanie E Siegmund, Sara E Wobker, Lara R Harik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2024
HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell TumorTom Zhang, Christopher A Febres-Aldana, Zebing Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell TumorKoichi Ogura, Romel Somwar, Julija Hmeljak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 14, 2023
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 AmplificationArielle Elkrief, Igor Odintsov, Vladimir Markov, et al.
Cancer Discovery|June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathwayPietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.
Disease Models & Mechanisms|December 15, 2020
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulationTakuo Hayashi, Igor Odintsov, Roger S Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 22, 2025
Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping MutationsFederica Pecci, Prashasti Agrawal, Jessica S Ross, et al.
Cancer Discovery|February 18, 2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapyChristopher A Febres-Aldana, Morana Vojnic, Igor Odintsov, et al.
Cancer Discovery|February 9, 2022
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene RearrangementsAlison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, et al.
Disease Models & Mechanisms|November 29, 2021
Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signalingRoger S Smith, Igor Odintsov, Zebing Liu, et al.
Pageof 20

Showing results (181-190 of 196) with videos related to

Sort By:
Pageof 20
Virchows Archiv : an International Journal of Pathology|May 21, 2026
Clinicopathologic characterization of renal tumors with Folliculin (FLCN) biallelic inactivationStephanie E Siegmund, Sara E Wobker, Lara R Harik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2024
HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell TumorTom Zhang, Christopher A Febres-Aldana, Zebing Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell TumorKoichi Ogura, Romel Somwar, Julija Hmeljak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 14, 2023
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 AmplificationArielle Elkrief, Igor Odintsov, Vladimir Markov, et al.
Cancer Discovery|June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathwayPietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.
Disease Models & Mechanisms|December 15, 2020
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulationTakuo Hayashi, Igor Odintsov, Roger S Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 22, 2025
Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping MutationsFederica Pecci, Prashasti Agrawal, Jessica S Ross, et al.
Cancer Discovery|February 18, 2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapyChristopher A Febres-Aldana, Morana Vojnic, Igor Odintsov, et al.
Cancer Discovery|February 9, 2022
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene RearrangementsAlison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, et al.
Disease Models & Mechanisms|November 29, 2021
Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signalingRoger S Smith, Igor Odintsov, Zebing Liu, et al.
Pageof 20